Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938.

Guedj J, Pang PS, Denning J, Rodriguez-Torres M, Lawitz E, Symonds W, Perelson AS.

Antivir Ther. 2014;19(2):211-20. doi: 10.3851/IMP2733. Epub 2014 Jan 24.

PMID:
24464551
2.

All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).

Lawitz EJ, Rodriguez-Torres M, Denning J, Mathias A, Mo H, Gao B, Cornpropst MT, Berrey MM, Symonds WT.

J Viral Hepat. 2013 Oct;20(10):699-707. doi: 10.1111/jvh.12091. Epub 2013 Mar 31.

PMID:
24010644
3.

Interferon-free strategies with a nucleoside/nucleotide analogue.

Feld JJ.

Semin Liver Dis. 2014 Feb;34(1):37-46. doi: 10.1055/s-0034-1371009. Epub 2014 Apr 29. Review.

PMID:
24782257
4.

Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.

Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, Symonds WT, McHutchison JG, Pang PS.

Gastroenterology. 2014 Mar;146(3):736-743.e1. doi: 10.1053/j.gastro.2013.11.007. Epub 2013 Nov 18.

PMID:
24262278
5.

Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).

Guedj J, Dahari H, Shudo E, Smith P, Perelson AS.

Hepatology. 2012 Apr;55(4):1030-7. doi: 10.1002/hep.24788. Epub 2012 Feb 15.

6.

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.

Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A.

Lancet Infect Dis. 2013 May;13(5):401-8. doi: 10.1016/S1473-3099(13)70033-1. Epub 2013 Mar 15.

PMID:
23499158
7.

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.

Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, Cornpropst MT, Mader M, Albanis E, Jiang D, Hebner CM, Symonds WT, Berrey MM, Lalezari J.

J Hepatol. 2013 Apr;58(4):663-8. doi: 10.1016/j.jhep.2012.11.018. Epub 2012 Nov 23.

PMID:
23183528
8.

Treatment of hepatitis C virus genotype 3-infection.

Pol S, Vallet-Pichard A, Corouge M.

Liver Int. 2014 Feb;34 Suppl 1:18-23. doi: 10.1111/liv.12405. Review.

PMID:
24373074
9.

Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus.

Summers BB, Beavers JW, Klibanov OM.

J Pharm Pharmacol. 2014 Dec;66(12):1653-66. doi: 10.1111/jphp.12294. Epub 2014 Aug 31. Review.

PMID:
25175944
10.

In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.

Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, Yan JM, So SS, Klumpp K, Nájera I.

J Infect Dis. 2014 Mar 1;209(5):668-75. doi: 10.1093/infdis/jit562. Epub 2013 Oct 23.

11.

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM.

N Engl J Med. 2013 Jan 3;368(1):34-44. doi: 10.1056/NEJMoa1208953.

12.

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P; ION-1 Investigators.

N Engl J Med. 2014 May 15;370(20):1889-98. doi: 10.1056/NEJMoa1402454. Epub 2014 Apr 11.

13.

Sofosbuvir for the treatment of hepatitis C virus.

Asselah T.

Expert Opin Pharmacother. 2014 Jan;15(1):121-30. doi: 10.1517/14656566.2014.857656. Epub 2013 Nov 30. Review.

PMID:
24289735
14.

A novel promising therapeutic option against hepatitis C virus: an oral nucleotide NS5B polymerase inhibitor sofosbuvir.

Gentile I, Borgia F, Buonomo AR, Castaldo G, Borgia G.

Curr Med Chem. 2013;20(30):3733-42. Review.

PMID:
23848533
15.

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.

Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR; POSITRON Study; FUSION Study.

N Engl J Med. 2013 May 16;368(20):1867-77. doi: 10.1056/NEJMoa1214854. Epub 2013 Apr 23.

16.

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW; ION-3 Investigators.

N Engl J Med. 2014 May 15;370(20):1879-88. doi: 10.1056/NEJMoa1402355. Epub 2014 Apr 10.

17.

Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?

Sofia MJ.

Antiviral Res. 2014 Jul;107:119-24. doi: 10.1016/j.antiviral.2014.04.008. Epub 2014 May 2.

PMID:
24792751
18.

Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection.

Rodríguez-Torres M.

Expert Rev Anti Infect Ther. 2013 Dec;11(12):1269-79. doi: 10.1586/14787210.2013.855126. Review.

PMID:
24215243
19.

Sofosbuvir as backbone of interferon free treatments.

Bourlière M, Oules V, Ansaldi C, Adhoute X, Castellani P.

Dig Liver Dis. 2014 Dec 15;46 Suppl 5:S212-20. doi: 10.1016/j.dld.2014.09.024. Epub 2014 Nov 6. Review.

20.

Sofosbuvir for previously untreated chronic hepatitis C infection.

Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ.

N Engl J Med. 2013 May 16;368(20):1878-87. doi: 10.1056/NEJMoa1214853. Epub 2013 Apr 23.

Items per page

Supplemental Content

Write to the Help Desk